ReviewCancers2021
Peritoneal Metastasis: Current Status and Treatment Options.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Radiomics-based machine learning in the prediction of peritoneal metastasis in ovarian cancer: a systematic review and meta-analysis.BMC medical imaging · 2025Pooled it
- Temporal Immune and Metabolic Shifts Drive the Anti-Tumor Efficacy of Resiquimod-Loaded Nanoparticles in Peritoneal Carcinomatosis.Advanced healthcare materials · 2026Article
- An appendiceal cancer organoid biobank identifies phenotypic evolution and druggable dependencies of peritoneal carcinomatosis.Developmental cell · 2026Article
- Endostar combined with docetaxel or cisplatin in the management of malignant ascites through hyperthermic intraperitoneal chemotherapy: A retrospective cohort study.Oncology letters · 2026Article
- Peritoneal Immunosurgery: Immunotherapy Augmented Surgery for the Treatment of Peritoneal Cancers.Journal of surgical oncology · 2025Review
- Real-world risk factors for incomplete cytoreduction in peritoneal carcinomatosis patients scheduled for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.World journal of surgical oncology · 2025Article
- Intraperitoneal infusion of NKG2D CAR-NK cells induces endogenous CD8Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Article
- Review
- Tumor exosomal circPTBP3 drives gastric cancer peritoneal metastasis via mesothelial-mesenchymal transition.Cell death & disease · 2025Article
- 3D printing injectable microbeads using a composite liposomal ink for local treatment of peritoneal diseases.Drug delivery and translational research · 2024Article
- CILP2 is a potential biomarker for the prediction and therapeutic target of peritoneal metastases in colorectal cancer.Scientific reports · 2024Article
- Emerging therapeutic approaches for peritoneal metastases from gastrointestinal cancers.Molecular therapy. Oncology · 2024Review
- Efficacy and Safety of Maintenance Therapy Using Cetuximab in Patients with Metastatic Colorectal Cancer: Retrospective Study.Cancer management and research · 2024Article
- Research progress of epithelial-mesenchymal transformation-related transcription factors in peritoneal metastases.Journal of Cancer · 2024Review
- A novel risk model for predicting peritoneal metastasis in colorectal cancer based on the SEER database.Journal of cancer research and clinical oncology · 2023Article
- Predictive Genetic Biomarkers for the Development of Peritoneal Metastases in Colorectal Cancer.International journal of molecular sciences · 2023Article
- Targeting Oncometabolites in Peritoneal Cancers: Preclinical Insights and Therapeutic Strategies.Metabolites · 2023Review
- DNA and RNA Alterations Associated with Colorectal Peritoneal Metastases: A Systematic Review.Cancers · 2023Review
- Activated Leukocyte Cell Adhesion Molecule (ALCAM), a Potential 'Seed' and 'Soil' Receptor in the Peritoneal Metastasis of Gastrointestinal Cancers.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Peritoneal metastasis (PM) originating from gastrointestinal cancer was considered a terminal disease until recently. The advent of better systemic treatment, a better understanding of prognostic factors, and finally, the advent of novel loco-regional therapies, has opened the door for the multimodal treatment of PM. These strategies, including radical surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) showed surprisingly good results, leading to the prolonged survival of patients with peritoneal metastasis. This has triggered a significant body of research, leading to the molecular characterization of PM, which may further help in the development of novel treatments. This review summarizes current evidence on peritoneal metastasis and explores potential novel mechanisms and therapeutic approaches to treat patients with peritoneal metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.